Pharmacological treatment of COVID-19: an opinion paper.
Rev Esp Quimioter
; 35(2): 115-130, 2022 Apr.
Article
in English
| MEDLINE | ID: covidwho-2230236
ABSTRACT
The precocity and efficacy of the vaccines developed so far against COVID-19 has been the most significant and saving advance against the pandemic. The development of vaccines has not prevented, during the whole period of the pandemic, the constant search for therapeutic medicines, both among existing drugs with different indications and in the development of new drugs. The Scientific Committee of the COVID-19 of the Illustrious College of Physicians of Madrid wanted to offer an early, simplified and critical approach to these new drugs, to new developments in immunotherapy and to what has been learned from the immune response modulators already known and which have proven effective against the virus, in order to help understand the current situation.
Keywords
AZD7442; Adalimumab; Anakinra; Azithromycin; BRII-196; BRII-198; Banlanivimab; Baricitinib; COVID-19; Canakinumab; Casirivimab; Certolizumab; Ciganilmab; Colchicine; Dexamethasone; Etanercept; Etesevimab; Evusheld; Favipiravir; Fluvoxamine; Golimumab; Hydroxychloroquine; Imdevinab; Infliximab; Itolizumab; Ivermectin; Lemilumab; Lopinavir/Ritonavir; Metformin; Molnupiravir; PF-07321332; Paxlovid; Ravulizumab; Remdesivir; Ruxolitinib; SARS-CoV-2; Sarilumab; Sotrovimab; Tixagevimab; Tocilizumab; Tofacitinib; Vitamin D; convalescent plasma; treatment
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
COVID-19 Drug Treatment
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Rev Esp Quimioter
Journal subject:
Drug Therapy
Year:
2022
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS